

We claim:

- 5 1. A process for producing crystals of a GLP-1 analogue comprising:
 - a) preparing an aqueous solution comprising a GLP-1 analogue, a salt, and an organic solvent, and
 - b) isolation of the crystals after formation.
- 10 2. The process according to claim 1 wherein in step a) adjusting pH to $pI-4 < pH < pI$, or to $pI < pH < pI+4$, wherein pI is the isoelectric point of the GLP-1 analogue.
3. The process according to any one of claims 1-2 wherein the crystals are needle shaped crystals of a GLP-1 analogue.
- 15 4. The process according to any one of claims 1-3 wherein the crystals has a length of at least $0.5\mu m$.
5. The process according to any one of claims 1-4 wherein the GLP-1 analogue in the aqueous solution has a purity of less than 95%, as measured by HPLC.
- 20 6. The process according to any one of claims 1-5 wherein the GLP-1 analogue in the aqueous solution is present in a concentration of at least 0.5 mg/ml.
- 25 7. The process according to any one of claims 1-6 wherein the GLP-1 analogue is selected from non-synthetic GLP-1 analogues.
8. The process according to any one of claims 1-7 wherein the GLP-1 analogue is Arg³⁴GLP-1(7-37) or Arg²⁶GLP-1(7-37).
- 30 9. The process according to any one of claims 1-8 wherein the salt is present in a concentration of at least 25 mM.
10. The process according to any one of claims 1-9 wherein the organic solvent is present in a concentration of from 0.5 to 50 %(vol/vol).
- 35

11. The process according to any one of claims 1-10 wherein the organic solvent is selected from C₁₋₆-alkanol, C₁₋₆-alkenol, C₁₋₆-alkynol, urea, guanidine, C₁₋₆-alkanoic acid, ketone, DMSO, C₂₋₆-glycol, C₃₋₇-polyalcohol including sugars, or mixtures thereof.

5 12. A method for producing a GLP-1 analogue or a GLP-1 analogue whereto is attached a lipophilic substituent comprising the steps:

- a) preparing an aqueous solution comprising a GLP-1 analogue, a salt, and an organic solvent, and
- b) isolation of the crystals after formation.

10

13. Crystals of a GLP-1 analogue obtainable by the process comprising:

- a) preparing an aqueous solution comprising a GLP-1 analogue, a salt, and an organic solvent, and
- b) isolation of the crystals after formation.

15

14. Needle shaped crystals of a GLP-1 analogue.

15. A pharmaceutical composition comprising needle shaped crystals of a GLP-1 analogue and a pharmaceutically acceptable carrier.

20